Purpose: To evaluate the incremental value of diffusion-weighted imaging (DWI) to conventional MR imaging (CMRI) to predict ipsilateral metastatic axillary lymphadenopathy in patients with newly diagnosed breast cancer.
The presence of LN metastases is the most important prognostic factor in both treatment planning and disease-related survival. 4, 5 Physical examination to assess the nodal status is usually associated with low sensitivity. 6 Ultrasonography (US) of the ipsilateral axilla is widely used to identify suspected or occult nodal metastasis, but morphological assessment alone has insufficient sensitivity and low positive predictive value (PPV). 7, 8 Therefore, ultrasound morphological evaluation is coupled with needle-guided biopsy to increase its accuracy. 7, 8 The role of conventional MR imaging (CMRI), to identify LN metastasis has been investigated, and revealed moderate sensitivity (range, 78%-94%) and low-to-moderate specificity (range, 63%-90%), 9, 10 mainly depending on the volume of axillary metastasis.
Therefore, there is a need for more precision in noninvasive presurgical diagnosis of axillary metastasis. Currently, sentinel LN biopsy (SLNB) and/or axillary dissection are the gold standard for the diagnostic evaluation of axillary LN metastases. 13 However, axillary surgery not only prolongs hospital stays but may also result in significant morbidity that may be worsened by subsequent radiation therapy. 14, 15 Diffusion-weighted imaging (DWI) of the breast has been applied as an adjunct to dynamic contrast-enhanced (DCE) Breast cancer tends to demonstrate more restricted diffusion than does normal breast tissue or benign breast lesions. 18 The use of an optimized ADC cutoff has been shown to improve breast lesion characterization without decreasing sensitivity, and it could reduce the number of negative biopsy results. 18, 19 Although multiple prior reports have suggested a benefit of supplemental DWI in evaluating breast lesions, 18, 19 to our knowledge, the usefulness of this technique for determining the presence of axillary LN metastases has been evaluated using ADC values only on small series in patients with large volumes of disease in the breast and the axilla. 21, 24, 25 These patients have a higher pretest probability of harboring metastatic disease which may be detected with conventional MR imaging alone, therefore it is unclear if this data are applicable to early-stage breast cancer patients with smaller volume of axillary metastasis. To address this gap in knowledge, we undertook this study to investigate the incremental benefit of adding DWI to CMRI for the diagnosis of ipsilateral metastatic axillary lymphadenopathy in patients with newly diagnosed breast cancer. 
| SUBJECTS AND METH ODS

| Patient selection and MRI technique
| Evaluation of CMRI and DWI
Conventional MR images were analyzed by consensus reading by two radiologists (IG and B. D.) who had 8 years of experience in interpreting breast MR examinations and were blinded to the final outcome of the axillary pathologic assessments. The single major criterion of ipsilateral LN metastasis was the identification of complete absence of the central fatty hilum on T1-and T2-weighted images in precontrast and postcontrast series. 13 If there was no loss of the fatty hilum, the presence of at least 2 of the following previously reported morphological features on the images were deemed diagnostic for metastatic disease, as previously described. 26, 27 These fea- To reduce the effects of partial volume artifacts, the smallest lymph node size for ADC calculation was set at a short-axial diameter of 1 cm. Quantitative analysis of the DWI series was performed by measuring the mean ADC of the index suspicious ipsilateral LN and taking the lowest mean calculated ADC value. When multiple lymph nodes were present, up to three measurements were made from representative lymph nodes. A ROI was traced within the cortical boundaries of each LN by using an electronic cursor. Care was taken to avoid including adjacent normal tissue or hilar fatty tissue.
We compared this value with those of a representative contralateral axillary LN measuring >1 cm, which was obtained in a similar manner.
| Histopathological evaluation
Pathological confirmation of LN status was obtained by US-guided needle biopsy, SLNB, or axillary LN dissection. Comparisons between histopathology results and both CMRI and ADC findings were performed for each patient. We made no attempt to make a node-tonode comparison of the specific LNs assessed by MR imaging with histopathological examination.
| Statistical analysis
To find the best cutoff value for ADC and control the ADC variable in identifying benign versus malignant LNs, we used the recursive partitioning method. After the best cutoff value was found, ADC values were grouped into "benign" and "malignant" levels based on this cutoff, and sensitivity, specificity, PPV, and NPV were calculated using the pathology readings as the gold standard. The receiver operating characteristic (ROC) curve was plotted, and the area under the curve was presented together with the ROC curve. For this particular analysis, data from all 85 patients were included. We calculated the sensitivity, specificity, PPV, and NPV for the CMRI method, also using the pathology readings as the gold standard. In addition, McNemar's test was used to compare the sensitivity and specificity between the DW and conventional MR imaging methods.
To identify predictors of axillary LN metastasis, a logistic regression model was used to estimate the probability (P) that a patient would develop axillary LN metastasis. The model predicted the natural log of the odds (log [P/1−P]) for a patient being in one category or the other. For this logistic regression analysis, only invasive cancer patients whose lesion grade was 1 or higher were included (n = 71).
The modeling was done in a univariate fashion. From this model, we estimated the odds ratio for each potential prognostic factor with a 95% confidence interval. All potential prognostic factors with a P value <0.10 from the univariate analysis were then included in a sat- Table 2 ). The difference in ADC values was significantly lower for ipsilateral malignant LNs than ipsilateral benign (P < 0.0001) or contralateral (P < 0.0001) control group LNs.
| RESULTS
The difference between the ADC values measured in patients with benign ipsilateral axillary histopathology, and the contralateral (control group) axillary LNs was not statistically significant (P = 0.62). added DWI and concluded that CMRI with added DWI cannot substitute SLNB for ruling out axillary metastasis of breast cancer. They proposed to improve diagnostic performance of axillary MR imaging by using lymph node-specific contrast agents. In another study, 45 they found that using lymph node-specific contrast agents increased the NPV of CMRI with added DWI like Nakai et al 25 At the higher end, the b-values used at each institution vary, but a previous study comparing multiple b-values 47 indicated that a value of 1000 s/mm 2 , which we used for our study, was optimal for DWI of the breast. Finally, we found that the quality of fat suppression, which was achieved in our DWI sequence using a spectral-spatial excitation pulse, can vary from patient to patient and depending on the shimming conditions. Poorly suppressed fat signals can cause severe degradation in the DWI quality and render the calculated ADC values unreliable. As an alternative, fat suppression techniques such as inversion recovery may be used for more consistent results, albeit at the expense of a lower signal to noise ratio.
| DISCUSSION
In summary, our study findings indicate that DWI significantly improves the noninvasive diagnosis of axillary LN metastases in patients with newly diagnosed breast cancer, and helps to select patients with a higher probability of metastatic disease and decrease the number of unnecessary biopsies. We recommend a combination of morphological analysis and ADC value measurements to increase accuracy.
ACKNOWLEDGEMENTS
MDACC faculty received support from the MD Anderson Cancer
Center Support Grant P30CA106672.
O R C I D
Ceren Yalniz http://orcid.org/0000-0003-3685-4799
Basak E. Dogan http://orcid.org/0000-0001-7024-093X
